Diosmin Alleviates Retinal Edema by Protecting the Blood-Retinal Barrier and Reducing Retinal Vascular Permeability during Ischemia/Reperfusion Injury

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Tong, Nianting ^a   Zhang, Zhenzhen ^a   Zhang, Wei ^a   Qiu, Yating ^a   Gong, Yuanyuan ^a   Yin, Lili ^a   Qiu, Qinghua ^a   Wu, Xingwei ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIOSMIN; OCCLUDIN; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN ZO1; VASCULOTROPIN;

A WAVE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B WAVE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ELECTRORETINOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; RETINA CAPILLARY; RETINA EDEMA; RETINA ISCHEMIA; RETINAL THICKNESS; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; DIOSMIN; ELECTRORETINOGRAPHY; EYE PROTEINS; MALE; NERVE GROWTH FACTORS; PAPILLEDEMA; RATS; REPERFUSION INJURY; RETINA; RETINAL NEURONS; SERPINS; TIGHT JUNCTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; RATTUS;

EID: 84876579314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061794     Document Type: Article

References (32)

1. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, et al. (2004) Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 23: 91-147.
2. Kaur C, Foulds WS, Ling EA, (2008) Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 27: 622-647.
3. Liu K, Sun T, Wang P, Liu YH, Zhang LW, et al. (2012) Effects of Erythropoietin on Blood-Brain Barrier Tight Junctions in Ischemia-Reperfusion Rats. J Mol Neurosci.
4. Ramelet AA, (2001) Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology 52Suppl 1: S49-56.
5. Smith PD, (1999) Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc Res 36Suppl 1: 24-36.
6. Bergan JJ, Schmid-Schonbein GW, Takase S, (2001) Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology 52Suppl 1: S43-47.
7. Le Devehat C, Khodabandehlou T, Vimeux M, Kempf C, (1997) Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp 17Suppl 1: 27-33.
8. Labrid C, (1994) Pharmacologic properties of Daflon 500 mg. Angiology 45: 524-530.
9. Ramelet AA, (2000) Pharmacologic aspects of a phlebotropic drug in CVI-associated edema. Angiology 51: 19-23.
10. Manthey JA, (2000) Biological properties of flavonoids pertaining to inflammation. Microcirculation 7: S29-34.
11. Tong N, Zhang Z, Gong Y, Yin L, Wu X, (2012) Diosmin protects rat retina from ischemia/reperfusion injury. J Ocul Pharmacol Ther 28: 459-466.
12. Silambarasan T, Raja B, (2012) Diosmin, a bioflavonoid reverses alterations in blood pressure, nitric oxide, lipid peroxides and antioxidant status in DOCA-salt induced hypertensive rats. Eur J Pharmacol 679: 81-89.
13. Zhong YS, Liu XH, Cheng Y, Min YJ, (2008) Erythropoietin with retrobulbar administration protects retinal ganglion cells from acute elevated intraocular pressure in rats. J Ocul Pharmacol Ther 24: 453-459.
14. Xu Q, Qaum T, Adamis AP, (2001) Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42: 789-794.
15. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, et al. (2006) Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 20: 323-325.
16. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, et al. (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180: 341-346.
17. Kaur C, Sivakumar V, Yong Z, Lu J, Foulds WS, et al. (2007) Blood-retinal barrier disruption and ultrastructural changes in the hypoxic retina in adult rats: the beneficial effect of melatonin administration. J Pathol 212: 429-439.
18. Kaur C, Sivakumar V, Foulds WS, (2006) Early response of neurons and glial cells to hypoxia in the retina. Invest Ophthalmol Vis Sci 47: 1126-1141.
19. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, et al. (2002) Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab 22: 379-392.
20. Spoerri PE, Afzal A, Li Calzi S, Shaw LC, Cai J, et al. (2006) Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells. Mol Vis 12: 32-42.
21. Fischer S, Wobben M, Marti HH, Renz D, Schaper W, (2002) Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc Res 63: 70-80.
22. Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, et al. (1999) VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 40: 1808-1812.
23. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, et al. (2001) Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276: 7614-7620.
24. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, et al. (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96: 10836-10841.
25. Cai J, Wu L, Qi X, Li Calzi S, Caballero S, et al. (2011) PEDF regulates vascular permeability by a gamma-secretase-mediated pathway. PLoS One 6: e21164.
26. Sheikpranbabu S, Ravinarayanan H, Elayappan B, Jongsun P, Gurunathan S, (2010) Pigment epithelium-derived factor inhibits vascular endothelial growth factor-and interleukin-1beta-induced vascular permeability and angiogenesis in retinal endothelial cells. Vascul Pharmacol 52: 84-94.
27. Yamagishi S, Abe R, Jinnouchi Y, Matsui T, Imaizumi T, et al. (2007) Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo. J Int Med Res 35: 896-899.
28. Yang J, Duh EJ, Caldwell RB, Behzadian MA, (2010) Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/beta-catenin signaling pathway and uPAR expression. Invest Ophthalmol Vis Sci 51: 3273-3280.
29. Zheng B, Li T, Chen H, Xu X, Zheng Z, (2011) Correlation between ficolin-3 and vascular endothelial growth factor-to-pigment epithelium-derived factor ratio in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 152: 1039-1043.
30. Pons M, Marin-Castano ME, (2011) Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD. Invest Ophthalmol Vis Sci 52: 3842-3853.
31. Fan W, Crawford R, Xiao Y, (2011) The ratio of VEGF/PEDF expression in bone marrow mesenchymal stem cells regulates neovascularization. Differentiation 81: 181-191.
32. Zheng Z, Chen H, Ke G, Fan Y, Zou H, et al. (2009) Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway. Diabetes 58: 954-964.